Feature | Cardiovascular Business | August 01, 2022 | By Melinda Taschetta-Millane

Top 10: What Viewers Were Reading in July

More than one in four pregnancy-related deaths (26.5%) in the U.S. are tied to poor heart health, especially among people of color, putting both parents-to-be and their babies at risk, according to the American Heart Association Heart Disease and Stroke Statistics 2022 Update.

Here is what you and your colleagues found to be most interesting in the fields of diagnostic and interventional cardiology during the month of July.

1. $20 Million Awarded for Research to Improve Outcomes in Pregnancy, Infant CVD Health

2. Ancora Heart Receives Breakthrough Device Designation from FDA for the AccuCinch Ventricular Restoration System

3. Henry Ford Health Hospitals Earn Highest Quality Recognition for Stroke Care from American Heart Association and American Stroke Association

4. VIDEO: Philips X5-1c Transducer, the Next Advancement in 3D Transthoracic Imaging

5. iRhythm Gains FDA Clearance for its Clinically Integrated ZEUS System

6. Breaking the Bottleneck: Training Tomorrow's Cardiac Device Technicians

7. VIDEO: Automation Features in Philips EPIQ CVx

8. A Closed-Loop Self-Powered Low-Level Vagus Nerve Stimulation System Based on Hybrid Nanogenerator for Atrial Fibrillation Treatment

9. VIDEO: Philips EPIQ CVx with Cardiac TrueVue for next level photorealistic 3D rendering

10. CardioFocus Announces Pulsed Field Ablation Milestones

Log in or register to post comments

Related Content

Japan’s PMDA asked for further details on a number of elements included in BioCardia’s CardiAMP preclinical and clinical packages in order to gain approval.

News | Heart Failure

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

November 30, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

November 30, 2023

Data from all three patients in non-randomized cohort treated with DSR 2.0 indicate safe and effective maintenance of euvolemia without the need for loop diuretics, considerable benefit in cardiorenal status and dramatic improvement in diuretic response and loop diuretic requirements up to 11 weeks post DSR treatment

News | Heart Failure

Sequana Medical Announces Positive Data from Non-randomized Cohort in US Phase 1/2a MOJAVE Study of DSR 2.0 for Treatment of Heart Failure

November 30, 2023 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

November 30, 2023

Findings will help scientists understand how microgravity impacts the ability of human heart cells to withstand the stresses of space travel

News | Heart Failure

Mount Sinai Bioengineers Send Cardiac Muscle Samples Into Space to Study Heart Cell Biology in Microgravity

November 16, 2023 — Mount Sinai’s Cardiovascular Research Institute is sending bioengineered human heart muscle cells ...

November 16, 2023

In the trial of more than 400 adults with heart failure in Israel, the app predicted the need for hospitalization about three weeks in advance of a heart failure event

News | Heart Failure

AI-phone App Detected Worsening Heart Failure Based on Changes in Patients’ Voices

November 16, 2023 — A smartphone app using artificial intelligence technology to detect changes in the voice of a person ...

November 16, 2023

The award recognizes leaders who have made major contributions to the fields of cardiovascular and stroke science

News | Heart Failure

American Heart Association Honors Gladstone President Deepak Srivastava with Distinguished Scientist Award

November 14, 2023 — Deepak Srivastava, MD, president of Gladstone Institutes and a renowned cardiovascular researcher ...

November 14, 2023

Ultromics, a leading health technology company at the forefront of detection of heart failure and its phenotypes, announces a significant development regarding the reimbursement code for its flagship product, EchoGo Heart Failure.

News | Heart Failure

CMS publishes final Clinical APC rule for Ultromics EchoGo Heart Failure

November 13, 2023 — Ultromics, a leading health technology company at the forefront of detection of heart failure and ...

November 13, 2023

New Board of Cardiovascular Medicine will certify cardiovascular medicine physicians with more specific and more competency-based trainings and supports

News | Heart Failure

The American Heart Association Joins Consortium with Full Support for a New American Board of Cardiovascular Medicine

November 3, 2023 — The national Board of Directors of the American Heart Association last week voted to provide full ...

November 03, 2023

Published late-breaking clinical data presented at TCT 2023

News | Heart Failure

Gene Discoveries Could Help Prevent Deadly Coronary Artery Disease

October 20, 2023 — An international team of scientists has identified nearly a dozen genes that contribute to calcium ...

October 20, 2023

Initial data indicate that DSR 2.0 is safe and well tolerated, restores diuretic response and improves cardiorenal status

News | Heart Failure

Sequana Medical Announces Initial Positive Data from MOJAVE, a US Phase 1/2a Study of DSR 2.0 for Treatment of Heart Failure Through Breaking Vicious Cycle of Cardiorenal Syndrome

October 18, 2023 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

October 18, 2023

Combination of Tenaya’s HDAC6 inhibitors with Empagliflozin Shows Additive Benefits in Preclinical HFpEF Model and Highlights Differentiated Mechanism of Action

News | Heart Failure

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

October 11, 2023 — Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop ...

October 11, 2023

© Copyright Wainscot Media. All Rights Reserved.